Research at Oslo University Hospital


Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.


Latest news

Institute seminar May 25th

Randi Gussgard Syljuåsen


The upcoming Institute Seminar at the Institute for Cancer Research will take place on Wednesday 25th of May at 12:00 in the Auditorium in the Research Building at Montebello with the following speaker:

Dr. Randi Gussgard Syljuåsen, Group Leader at Dept. Radiation Biology, Institute for Cancer Research

Title of her talk: "Inhibition of DNA damage checkpoint kinases for cancer treatment: mechanisms and strategies"


Strønen and Olweus publish article in Science on the use of donor immunity to target cancer

Strønen and Olweus
Strønen and Olweus

Erlend Strønen and Johanna Olweus from the Department of Immunology at the Institute for Cancer Research and the K.G. Jebsen Centre for Cancer Immunotherapy are first and joint last author respectively on a paper recently (May 19th) published in Science (journal impact factor 33.6), entitled "Targeting of cancer neoantigens with donor-derived T cell receptor repertoires".
The international research team - based in Oslo, Amsterdam and Copenhagen - has made a breakthrough methodological development in generating broad and tumour-specific T-cell immune responses based on a novel allogeneic approach. This is a powerful technological advancement which can in the relatively near future be subjected to clinical testing.


Håvard Danielsen and Erik Fosse receive Lighthouse project grants from the Norwegian Research Council

Håvard Danselsen (left), Tine Nordgreen (INTROMAT) and Erik Fosse.
Håvard Danselsen (left), Tine Nordgreen (INTROMAT) and Erik Fosse.

Oslo University Hospital heads projects DoMore! led by Håvard Danielsen from the Institute for Cancer Genetics and Informatics and BIGMED led by Erik Fosse from the Intervention Centre project receive Lighthouse project grant from the Norwegian Research Council's IKTPLUSS area of commitment. The funding for each project is 60 million NOK over a five-year period. 
There were 76 research teams competing for the prestigious grant and only three winners- The third project is INTROMAT, led by Tine Nordgreen from UiB.
The ​DoMore!​ ​team ​is composed ​of experts within several fields, including digital imaging, processing, robotics, pathology, cell biology, surgery and oncology, both in Norway and abroad​​.
The vision behind the BIG data MEDical solution (BIGMED) is to lay the foundation for an ICT platform that addresses the analytic bottlenecks for the implementation of precision medicine, and paves the way for novel big data analytics.


OUS scientists partners in project funded by HORIZON 2020 FAST TRACK TO INNOVATION

"Intelligent needle tracking using ultrasound imaging for improved minimally invasive interventions" supported by EU

Axel R. Sauter (left) and Leiv Arne Rosseland
Axel R. Sauter (left) and Leiv Arne Rosseland

Philips, B.Braun and Oslo University Hospital are partnering in the EU funded INTUI-VIEW project to develop, validate, and bring to the market an intelligent needle tracking technology using ultrasound imaging. The aim of this project is to reliably visualize the needle position in relation to the patient’s anatomy, under ultrasound guidance. The INTUI-VIEW project has been granted €2.36 million.
The participants representing OUH in the project are Axel R. Sauter and Leiv-Arne Rosseland (photo) from the Division of Emergencies and Critical Care at Oslo University Hospital. OUH will receive € 75000 for use in this project, which will be running approximately for 3 years.


OUS scientists co-author Nature article:

Mapping somatic mutations in breast cancer whole genomes

From left: Miriam R. Aure, Ole Chr. Lingjærde, Anita Langerød and Anne-Lise Børresen-Dale
From left: Miriam R. Aure, Ole Chr. Lingjærde, Anita Langerød and Anne-Lise Børresen-Dale

The most comprehensive analysis to date of somatic (acquired) mutations, across whole-genome sequences for breast cancer, is reported in a paper published in the May 2nd edition of Nature (journal impact factor 41.5).
Miriam R. Aure, Anita Langerød, Ole Christian Lingjærde, and Anne-Lise Børresen-Dale from the "Molecular biology of breast cancer group" at the Department of Cancer Genetics has contributed substantially to the study.
A related paper, published in Nature Communications, explores how these mutations relate to aspects of genome structure. Together, the studies highlight the repertoire of genes and mutational processes involved in breast cancer and move us closer to a more complete account of the genetic basis of the disease.


Institute for Cancer Research annual report 2015


2015 has been a very good year for ICR, and areas for further improvement include increases in collaboration with clinical researchers, partnerships and coordinator roles in more successful EU grants, and strengthened international visibility. 

Read all the details in the recently published annual report.


Same, but different? Genetic analysis of five immune mediated diseases reveals molecular taxonomy of chronic inflammation

Tom Hemming Karlsen
Tom Hemming Karlsen

A genetic analysis recently published in Nature Genetics (journal impact factor 29.35) sheds new light on the high comorbidity between primary sclerosing cholangitis (PSC) and inflammatory bowel disease.
Researchers from four large disease consortia, encompassing hundreds of researchers from 26 countries, joined forces to combine data from studies of their respective diseases, amounting to 52,262 patients and 34,213 healthy controls.
“This study is important because it creates a platform for understanding the molecular make-up of each disease, in the future enabling more specified treatment of chronic inflammatory disease”, says Tom Hemming Karlsen, coordinator of one of the participating consortia.


Article published in Science Translational Medicine showing that cyclodextrin may reduce atherosclerosis attracts worldwide attention

Halvorsen (left) and Skjelland
Halvorsen (left) and Skjelland

Two OUS researchers - professor Bente Halvorsen from the Research Institute of Internal Medicine, and head physician Mona Skjelland from the Department of Neurology - have together with professor Terje Espevik and post doc Siril Bakke from NTNU participated in a large international research project where they have shown that cyclodextrin may reverse atherosclerosis. The study is run by a German research group led by professor Eicke Latz, and the results were recently published in Science Translational Medicine (journal impact factor 18.54). The research has also received widespread attention from various places, including two highly profiled articles in the major newspaper Wall Street Journal.
(story updated with more links to articles from various news sources, under "More")


The Fridtjof Nansen Award for Young Scientists for 2016 to Kyrre Eeg Emblem

Kyrre E. Emblem
Kyrre E. Emblem

The Fridtjof Nansen Award of Excellence is awarded to Norwegian researchers, or researchers resident in Norway, who has shown scientific contributions of international significance on a very high level.

Fridtjof Nansen Award for Young Scientists for 2016 is divided between Professor Magne Mogstad at the Department of Economics, University of Chicago, for his outstanding research in the fields of economics and Principal Investigator Kyrre Eeg Emblem from the Intervention Centre at Oslo University Hospital, for his outstanding contribution to medical diagnostics.

The awards are presented by the chairman of The Nansen Foundation and Affiliated Funds, Professor Øyvind Østerud, on the Annual meeting of The Norwegian Academy of Science and Letters on Tuesday 3 May, 2016 at the Grand Hotel, Oslo.


Theodossiou and Berg funded by the Future and Emerging Technology (FET) program

Kristian Berg (left) and Theodossis Theodossiou
Kristian Berg (left) and Theodossis Theodossiou

Theodossis Theodossiou and Kristian Berg from the Photochemical internalisation (PCI) group at the Department of Radiation Biology have been funded by the Future and Emerging Technology (FET) program under the Excellent Science section of the Horizon 2020 EU Framework for Research and Innovation. The FET program funded this time 11 projects out of 820 grant applications (1,4 % success rate) and the proposal by Theodossiou and Berg was rated as no. 6. The project receives 3 million Euros together with 3 collaborating academic partners as well as one commercial partner (SME) from UK. The project, named Lumiblast, will be coordinated by Kristian Berg. This is the first time Norway is the coordinator of a FET project.